Trilaciclib Disease Interactions

The use of trilaciclib is not recommended in patients with moderate or severe liver dysfunction as its pharmacokinetics have not been studied in these patients. No dosage adjustment is recommended for patients with mild liver dysfunction.

The administration of cyclin-dependent kinases 4/6 inhibitors such as trilaciclib can cause severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis. It is recommended to exercise caution when using this agent in patients with a history of ILD and/or pneumonitis. Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Interrupt and evaluate patients with new or worsening symptoms suspected to be due to ILD/pneumonitis. Permanently discontinue treatment in patients with recurrent symptomatic or severe/life-threatening ILD/pneumonitis.

No clinically significant differences in the pharmacokinetics of trilaciclib were observed in patients with mild to moderate renal dysfunction. The effect on the pharmacokinetics in patients with severe renal dysfunction, end-stage renal dysfunction, or dialysis has not been studied. Care should be exercised when using this agent in these patients.